For advanced NSCLC patients with PD-L1 expression on less than 1% of TC or regardless of this expression, pembrolizumab or nivolumab or atezolizumab could be used in second-line therapy in patients who have not previously received immunotherapy (1–14). The gene discussed is CD274; the disease is non-small cell lung carcinoma.